Started a BRAF Colorectal Cancer Public Library group on Facebook. So many significant trials, research findings, changes to NCCN guidelines, etc. in the last 2 years. Gathering high level research/interviews into 1 place seems wise and useful. #BRAFCRC facebook.com/groups/20849066…

Wonderful interview with Dr @EileenMOReilly Hope given in a difficult diagnosis. Kindness embodied. @MSK_DeptOfMed

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors pan-KRAS inhibitor phase 1 trial , 434 pts Opened in August 2025 International trial - 35 sites US, Australia, Italy, France, South Korea, Japan, the UK, Belgium, Canada, China, Denmark, Germany, Netherlands, Spain clinicaltrials.gov/study/NCT…

At #AACR2026, prelim results from the investigator-sponsored #BBOpCo study led by Nicholas DeVito from Duke, will be presented evaluating #BOT BAL in 1L MSS #CRC. A shift toward using IO earlier to potentially reduce reliance on chemo surgery. Release: bit.ly/3KSL3Qw

Most assume Phase 1 oncology trials end early because of toxicity In reality, strategic sponsor decisions is the leading cause A difficult reality for patients who volunteer, accept risk, and place hope in research @VivekSubbiah @pash22 @DavidHongMD academic.oup.com/jnci/articl…

Looks like exactly the sessions patients want to see! @FightCRC @thequeenvee

Meet the biomarker leaders shaping the IMPACT-CRC project. IMPACT-CRC is a 🇪🇺 research project working to improve immunotherapy for people with colorectal cancer. Learn more about IMPACT-CRC here 👉  digestivecancers.eu/eu-funde… #IMPACTCRC #ColoRectalCancer #Immunotherapy

Now enrolling! Angela Bradbury MD @PennCancer leads @ALLIANCE_org A232301CD seeing if digital chatbot intervention is as effective as standard remote genetic services in increasing counseling uptake among #AYA #cancer patients bit.ly/AllianceA232301CD #AYACancerAwareness

Was at @KPSanFrancisco & shared with staff. Such an amazing local Bay Area story... From @kevansf at @UCSF to local @RevMedicines to Kaiser, Oakland oncologist! A lot to be proud of, so many wonderful Bay Area people w/ heart & brains! @sfchronicle @KTVU @kron4news @aboutKP

#asco26 Colorectal cancer

What a privilege to have @TheVinodLab visit @StanfordCancer for the Breakthroughs in Cancer series. Courageous and inspiring work on PCVs in #PDAC. Thank you for sharing the journey with us!

I'm looking forward to hosting @PanCAN's upcoming virtual event, KRAS and Pancreatic Cancer: Entering a New Era of Treatment. Join us as we discuss this pivotal moment in #KRAS research and what the latest discoveries may mean for patients today and in the future.

We do actually have a more clinically meaningful measure here: which is progression free survival (PFS) at 6 months. For combination, it's at 90%. The equivalent PFS at 6 months was 65% for daraxonrasib alone and lower for vopimetostat.

Vopimetostat works very differently, through a strategy called synthetic lethality. This means exploiting a vulnerability that is unique to cancer cells. ~ 35% of pancreatic cancers have lost the MTAP gene. That loss causes a metabolite called MTA to build up in tumour cells.

Im very glad @RevMedicines decided to take that meeting with Tango Therapeutics x.com/stepsequence100/status…

Data from Tango slide deck of PRMT5inh plus KRASinh (Daraxonrasib, left and Zoldonrasib, right) in 2nd/3rd line #PancreaticCancer ir.tangotx.com/static-files/… In this recent study (Boston Gene), ~20% of pancreatic cancers have KRAS mut plus MTAP co-deletion. aacrjournals.org/clincancerr…

The RAS revolution continues! Tango Therapeutics' new results date back to the discovery of a synthetic lethal interaction, in 2016: PRMT5 inhibition selectively kills cancer cells deficient in MTAP — about 40% of pancreatic cancer — while ~sparing normal cells This mechanism itself is probably independent of RAS, but given RAS inhibition is the likely future foundation of therapy, Tango's PRMT5 inhibitor, Vopimetostat, was tested in combination with RevMed's RAS inhibitor, Daraxonrasib — in MTAP-deficient pancreatic cancer Today's data come from a small number of patients, but the 6-month progression-free survival was 90% (compared, cross-trial, with Daraxonrasib alone, ~56%)

Top line data from Tango Therapeutics PRMT5 inh (Vopimetostat) plus @RevMedicines Daraxonrasib or Zoldonrasibin 2nd line #PancreaticCancer ir.tangotx.com/news-releases… Daraxonrasib (left) and Zoldonrasib (right) combination data. MultiRAS inhibition better than allele specific.